Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
화요일, 9월 01

Dr Reddy's Laboratories Ltd

RDYNYSE
Trade with Public
Trade with Public
$12.19
0.0550.45%
마지막 업데이트: Sep 1, 11:42 AM
개요뉴스실적 전망이벤트목표가재무심리배당금비교옵션주식 보고서

Dr Reddy's Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dr Reddy's Laboratories (RDY).

Price Target Range — 5 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingOverweight# Analysts2Avg. Consensus PT$17Upside to Avg. PT+39.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 5, 2025HSBCDamayanti Kerai UpgradeHold→Buy$14→$17
Nov 6, 2024BarclaysBalaji PrasadMaintainedOverweight$17→$17
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HSBC Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $16.9

HSBC analyst Damayanti Kerai upgrades Dr Reddy's Laboratories (NYSE:RDY) from Hold to Buy and raises the price target from $14.44 to $16.9.
Benzinga Newsdesk

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Vandana Singh

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $81 to $87.
Benzinga Newsdesk

Dr. Reddy's to Acquire Haleon's Nicotine Addiction Drug

Dr.
Zacks

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $80 to $81.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $80

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $75 to $80.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved